CATHEDRA BITCOIN INC
CBTTF
DMG BLOCKCHAIN SOLUTIONS INC
DMGGF
Ebang International
EBON
Bitdeer Technologies
BTDR
NEPTUNE DIGITAL ASSETS CORP
NPPTF
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.